Abstracts tagged "Rheumatoid Factor"

Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Corinne Kowal¹, Carey Shive^2,3, Elizabeth Zebrowski^4,5, Lenche Kostadinova^1,6, Brianna Fuller^1,6, Elane Reyes², Kelsey Rife⁴, Amy Hirsch⁴, Anita Compan⁴, Shyam Kottilil⁷, Yngve Falck-Ytter^6,8, Leonard H. Calabrese⁹, Donald Anthony^4,6,10,11 and Maya Mattar^6,12, ¹Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, ²Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, ³VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH, ⁵Department of Medicine, Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University, Cleveland, OH, ⁷IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, ⁸Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, ⁹Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, ¹¹VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, ¹²Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
Abstract Number: 72 • 2017 ACR/ARHP Annual Meeting
The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients
Onno J. Arntz¹, Bartijn C.H. Pieters¹, Rogier Thurlings², Peter M. van der Kraan³, F van den Hoogen² and Fons A.J. van de Loo³, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Rheumatology, Radboudumc, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Tumor-necrosis factor (TNF)-α plays a key role in the pathophysiology of rheumatoid arthritis (RA) and membrane bound TNFα is sufficient to induce arthritis in…
Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting
Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients
Annelies Blanken¹, Marian van Beers-Tas¹, Marlies Meursinge Reynders¹ and Dirkjan van Schaardenburg^1,2, ¹Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
Abstract Number: 480 • 2017 ACR/ARHP Annual Meeting
ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance
Raul Castellanos-Moreira Sr.¹, Virginia Ruiz-Esquide¹, María José Gomara², Sonia Cabrera-Villalba¹, Sebastian C Rodriguez-Garcia¹, Georgina Salvador³, Andrea Cuervo¹, Julio Ramírez¹, M. Victoria Hernández¹, Juan Cañete¹, Isabel Haro² and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, ³Hospital Universitario Mutua Terrassa, Barcelona, Spain
Background/Purpose: Autoantibodies (RF or ACPA) are found in sera from patients with palindromic rheumatism (PR) but there are no studies analyzing the presence of Anti-carbamylated…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 491 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 496 • 2016 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Ee Tzun Koh¹, Angela Marie Chan¹, Wei Qiang See², Wenwei Xiang², Khai Pang Leong¹ and Tan Tock Seng Rheumatoid Arthritis Study Group, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine…
Abstract Number: 505 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Carl Orr, Francis Young and Douglas J. Veale, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland
Background/Purpose: In recent years several studies suggest that first order stratification of RA should be based on the presence or absence of rheumatoid factor (RF)…
Abstract Number: 552 • 2016 ACR/ARHP Annual Meeting
Disability in Early Rheumatoid Arthritis, Course and Predictors
Therese Hansson^1,2, Christina Book^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,2, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose: Patient reported outcome measures (PROMs), including the Health Assessment Questionnaire Disability Index (HAQ-DI), are valuable and reliable instruments for assessment of disease severity and…
Abstract Number: 579 • 2016 ACR/ARHP Annual Meeting
MRI-Detected Osteitis Is Not Associated with the Presence or Level of ACPA Alone, but with the Combined Presence of ACPA and RF
Debbie M. Boeters¹, Wouter P. Nieuwenhuis¹, Marije K. Verheul¹, Elize C. Newsum¹, Monique Reijnierse², René E.M. Toes¹, Leendert A. Trouw¹ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Within rheumatoid arthritis (RA) bone marrow edema (BME, osteitis) and anti-citrullinated protein antibodies (ACPAs) are associated with radiographic progression. ACPA has been associated with…
Abstract Number: 988 • 2016 ACR/ARHP Annual Meeting
Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Søren Andreas Just¹, Kjell Titlestad², Gustaf Edgren³, Klaus Rostgaard⁴, Johan Askling⁵, Hanne Lindegaard¹ and Henrik Hjalgrim⁴, ¹Department of Rheumatology, Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, ²Department of Clinical Immunology, Department of Clinical Immunology, Odense Unversity Hospital, Odense, Denmark, Odense, Denmark, ³Department of Medical Epidemiology and Biostatistics, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Epidemiology Research, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, Copenhagen, Denmark, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a disease that can have a long sub-clinical phase. During this phase the person with pre-RA could have factors in…
Abstract Number: 1589 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
R Alten¹, H-M Lorenz², HG Nüßlein³, X Mariette⁴, M Galeazzi⁵, A Cantagrel⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³University of Erlangen, Nürnberg, Germany, ⁴Université Paris-Sud, Paris, France, ⁵University of Siena, Siena, Italy, ⁶Purpan Hospital, Toulouse, France, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: In patients with RA, obesity may impair clinical response to anti-TNF agents.1,2 In contrast, BMI does not appear to impact treatment retention or clinical…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…

« Previous Page
1
…
7
8
9
10
11
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].